- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03244267
App Reminder on ASA Adherence
Impact of a Smartphone App Reminder on Adherence Aspirin Prescribed as Anti-Thrombotic Therapy
The purpose of this study is to explore the impact of using a smartphone app reminder on medication adherence twice daily in adults prescribed 81 milligrams of aspirin for 35 days as anti-thrombotic therapy after knee or hip arthroplasty.
This study will randomly assign participants to get usual postoperative care which is teaching with verbal instructions and printed information about taking the aspirin at the time of discharge, or to have an app on your smartphone with preset reminders in addition to usual postoperative discharge teaching after surgery.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The purpose of this study is to evaluate the impact of using a smartphone application (app) reminder on medication adherence twice daily in 200 adults prescribed 81 milligrams of aspirin (ASA) for 35 days as anti-thrombotic therapy after knee or hip arthroplasty. The aim is to determine if an app downloaded on a smartphone that reminds patients twice a day to take their ASA as prescribed will improve ASA adherence and clinical outcomes for patients after total knee and total hip joint arthroplasty compared to those in the usual care.
This is a two group, randomized control study with random assignment into the control group for usual care or the intervention group to receive a medication reminder app for their smart phone (daily for 35 days) plus usual care. Participants will receive a baseline interview for demographic and other data and 36 day follow-up assessment, both conducted in person.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30084
- Emory Orthopedic and Spine Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Prescribed aspirin 81 mg twice a day for 35 days
- Ability to write and speak English
- Have a smart phone with the capacity to download and set an app
- Own and use a smart phone for communication purposes
Exclusion Criteria:
- Diagnosis of mental illness
- Do not own a smart phone
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Standard Education
Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
|
Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
|
|
Experimental: Medication Reminder App + Standard Education
Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
|
Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle.
The app will alert participants when it is time (selected by the participant) to take their medication.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Pills Taken
Zeitfenster: Post- Operative Visit (Day 36)
|
The proportion of pills taken is defined as the percentage of pills taken by study participants.
|
Post- Operative Visit (Day 36)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
AIDS Clinical Trials Group (ACTG) Adherence Questionnaire Score
Zeitfenster: Post- Operative Visit (Day 36)
|
The ACTG Adherence Questionnaire consists of 19 items measuring different aspects of efficacy (or confidence) in the management of one's medication.
Each item is rated from 0 ("I cannot do at all") to 10 ("Sure I can do"), with total scores found by summing responses to individual items and dividing by 19.
Higher scores correspond to higher levels of medication self-efficacy.
|
Post- Operative Visit (Day 36)
|
|
Aspirin (ASA) Self-Efficacy Scale Score
Zeitfenster: Post- Operative Visit (Day 36)
|
The ASA Self-Efficacy Scale consists of 19 items measuring different aspects of efficacy (or confidence) in the management of one's medication.
Each item is rated from 0 ("I cannot do at all") to 10 ("Sure I can do"), with total scores found by summing responses to individual items and dividing by 19.
Higher scores correspond to higher levels of medication self-efficacy.
|
Post- Operative Visit (Day 36)
|
|
Number of Thromboembolic Events
Zeitfenster: Post- Operative Visit (Day 36)
|
Clinical outcomes will be assessed at follow-up by self-report questions to ascertain if any thromboembolic events occurred.
|
Post- Operative Visit (Day 36)
|
|
Aspirin (ASA) General Adherence Scale Score
Zeitfenster: Post- Operative Visit (Day 36)
|
The ASA General Adherence Scale measures the ease and ability to adhere to the ASA regimen as prescribed.
It is scored by summing responses to the individual items and creating a total score.
Higher scores indicate better self-reported adherence.
|
Post- Operative Visit (Day 36)
|
|
Unified Theory of Acceptance and Use of Technology (UTAUT2) Survey Score
Zeitfenster: Baseline (Pre-Intervention)
|
The UTAUT2 measures antecedents (performance expectancy, effort expectancy, hedonic motivation) and behavioral intent to use mobile apps.
Items are scored using a 7-point Likert scale, from 1 (strongly disagree) to 7 (strongly agree).
Survey totals range between 14 and 112.
Higher scores are indicative of greater acceptance and intent to adopt the target technology.
|
Baseline (Pre-Intervention)
|
|
Performance Expectancy Subscale Score
Zeitfenster: Baseline (Pre-Intervention)
|
The Performance Expectancy Subscale measures the perceived benefits of mobile app technology to the consumer.
Scores range from 4 to 28, with higher totals indicating better perceptions of technology-related benefits.
|
Baseline (Pre-Intervention)
|
|
Effort Expectancy Subscale Score
Zeitfenster: Baseline (Pre-Intervention)
|
The Effort Expectancy Subscale measures the ease with which the consumer can learn and operate an app.
Scores range from 4 to 28, with higher totals indicating greater beliefs that the technology is easy and accessible.
|
Baseline (Pre-Intervention)
|
|
Hedonic Motivation Subscale Score
Zeitfenster: Baseline (Pre-Intervention)
|
The Hedonic Motivation subscale measures the enjoyment, the consumer experiences from using an app.
Respondents answer each item on a 7-point Likert-type scale ranging from 1 (Absolutely True) to 7 (Absolutely Untrue).
Scoring is kept continuous with higher scores indicating greater enjoyment.
|
Baseline (Pre-Intervention)
|
|
Behavioral Intent Subscale Score
Zeitfenster: Baseline (Pre-Intervention)
|
The Behavioral Intent Subscale measures the decision to use a mobile app.
Scores range from 3 to 21, with higher totals indicating a greater intent to use or adopt an app.
|
Baseline (Pre-Intervention)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Deborah Wittig-Wells, PhD, Emory University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IRB00094970
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Standard Education
-
University of SaskatchewanSaskatchewan Health Research Foundation; Royal University Hospital FoundationAbgeschlossen
-
Fu Jen Catholic University HospitalRekrutierungChronische Nierenerkrankung (CKD) | CKD-Stadium 1-3Taiwan
-
Mardin Artuklu UniversityRekrutierungLabor; Schlecht, PrimärTürkei (türkiye)
-
Istanbul University - CerrahpasaAnmeldung auf EinladungChirurgie | Risse in der Rotatorenmanschette | Schmerzen, SchulterTruthahn
-
Inonu UniversityNoch keine Rekrutierung
-
Abby GeerlingsAbgeschlossenAngst | Mitralinsuffizienz | Virtuelle Realität | Mitraclip | Trikuspidalinsuffizienz (TR) | TriClipNiederlande
-
Aydin Adnan Menderes UniversityRekrutierungSchwangerschaft | Ausbildung | Geburt | Geburtszufriedenheit | GeburtsgedächtnisTruthahn
-
Saglik Bilimleri UniversitesiAbgeschlossenPflegeausbildung | Frauengesundheit | Klimawandel | Nachhaltige EntwicklungTürkei (türkiye)
-
Istanbul Aydın UniversityAbgeschlossenStudenten der KrankenpflegeTürkei (türkiye)
-
Saglik Bilimleri UniversitesiAbgeschlossenHumanes Papillomavirus (HPV)Truthahn